Treatment Advances in Idiopathic Pulmonary Fibrosis: Recent Guidelines and Evidence to Support Optimal Patient Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive of the live session from the 2021 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2021 – August 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Boehringer Ingelheim

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial lung disease (ILD) of unknown origin characterized by progressive lung scarring. It is the most common of the idiopathic interstitial pneumonias, and is a devastating disease associated with irreversible destruction of the lung. The scarring in the lungs gets progressively worse and it makes it difficult for patients to breathe as well as keep adequate levels of oxygen in the bloodstream. The condition affects approximately 3 million people worldwide and has a substantial burden to patients, their families, and the overall healthcare system. Patients with IPF can progress slowly with the right treatment, while others experience rapid lung decline, which presents several diagnostic and management-related challenges. IPF typically has a poor prognosis and the median survival rate is less than four years or fewer from diagnosis. Most patients with idiopathic pulmonary fibrosis present with a gradual onset, which makes it difficult to diagnosis early.

In recent years, updated guidelines for the management of IPF were published to provide clinicians and healthcare providers the best management strategies for a proper diagnosis of IPF. The diagnosis of IPF in most cases involves an in-depth review of both medication and environmental exposure histories followed by a high-resolution computed tomography scan (HRCT). Depending on the results of the HRCT, an analysis of the bronchoalveolar lavage fluid or surgical lung biopsy may be performed, and with a proper evaluation of the HRCT results combined with a histopathology pattern, confirms a diagnosis of IPF. Healthcare professionals are constantly looking at ways to diagnose the disease much earlier to improve outcomes. Once the diagnosis is confirmed, the goals of IPF management are to ameliorate symptoms, improve health status, preserve lung function, maintain adequate oxygenation with supplemental oxygen, minimize adverse events of therapy, reduce the frequency of acute exacerbations and, ideally, improve overall patient care and outcomes.

Upon completion of this activity, participants will be able to:

  • Describe how to use current guidelines for evidence-based approaches to the treatment of idiopathic pulmonary fibrosis (IPF)

  • Explore best practices for the early and accurate diagnosis of IPF

  • Evaluate the evidence on the efficacy, safety, and utility of antifibrotic therapies for IPF to guide personalized treatment decisions

  • Assess pharmacologic and non-pharmacologic treatment selections for patients with IPF that help to preserve lung function and manage symptoms

  • Discuss multidisciplinary and patient-focused strategies to support the management of side effects associated with antifibrotic agents


Faculty: Fernando J. Martinez, MD
Professor of Medicine
Weill Cornell Medicine


Dr. Martinez has served on the Advisory Committee for Abbvie, AstraZeneca, Bayer, Boehringer Ingelheim, ProterrixBio, Bristol Myers Squibb, Bridge Biotherapeutics, Chiesi, Csl Behring, DevPro, Gala, Genentech, GlaxoSmithKline, IQVIA, Novartis, Polarean, Raziel, Sanofi, Sanofi/Regeneron, Shionogi, Teva, twoXR, United Therapeutics, Veracyte, Verona, Zambon. Dr. Martinez has served on the Steering Committee for Afferent/Merck, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Chiesi, Gilead, GlaxoSmithKline, Patara/Respivant, ProMedior/Roche, Sanofi/Regeneron, Veracyte. Dr. Martinez has served on the Adjudication Committee for Bayer, Boehringer Ingelheim, Biogen, Gilead, GlaxoSmithKline, Medtronic. He has also contributed to CME programs for Academy for Continuing Healthcare Learning, CME Outfitters, Integritas, Integrity Communications, MedScape, Miller Communications, NACE/Haymarket, PeerView, Physician Education Resource, Projects in Knowledge, UpToDate, Vindico, WebMD.
  Planning Committee:
Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Boehringer Ingelheim

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue